204 related articles for article (PubMed ID: 14523472)
1. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL.
Appel IM; Pinheiro JP; den Boer ML; Lanvers C; Reniers NC; Boos J; Pieters R
Leukemia; 2003 Nov; 17(11):2254-6. PubMed ID: 14523472
[No Abstract] [Full Text] [Related]
2. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
3. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
[TBL] [Abstract][Full Text] [Related]
5. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4
Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL
Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253
[TBL] [Abstract][Full Text] [Related]
6. PEG-asparaginase.
Fu CH; Sakamoto KM
Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798
[TBL] [Abstract][Full Text] [Related]
7. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
[TBL] [Abstract][Full Text] [Related]
8. Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study.
Rizzari C; Lanvers-Kaminsky C; Valsecchi MG; Ballerini A; Matteo C; Gerss J; Wuerthwein G; Silvestri D; Colombini A; Conter V; Biondi A; Schrappe M; Moericke A; Zimmermann M; von Stackelberg A; Linderkamp C; Frühwald MC; Legien S; Attarbaschi A; Reismüller B; Kasper D; Smisek P; Stary J; Vinti L; Barisone E; Parasole R; Micalizzi C; Zucchetti M; Boos J
Haematologica; 2019 Sep; 104(9):1812-1821. PubMed ID: 30705097
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Gajjar AJ; Sandlund JT; Harrison PL; Wang B; Pui CH; Relling MV
J Clin Oncol; 1999 May; 17(5):1568-73. PubMed ID: 10334545
[TBL] [Abstract][Full Text] [Related]
10. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
11. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
Thomas X; Cannas G; Chelghoum Y; Gougounon A
Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Chemother Pharmacol; 1993; 32(4):310-4. PubMed ID: 8324873
[TBL] [Abstract][Full Text] [Related]
15. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of PEG-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Pinheiro JP; Lanvers C; Würthwein G; Boos J
Blood; 2002 Sep; 100(5):1923-4; author reply 1924-5. PubMed ID: 12211194
[No Abstract] [Full Text] [Related]
17. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
18. [Advances on the role of pegaspargase in the treatment of childhood leukemia].
Liu L; Xie XT
Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909
[TBL] [Abstract][Full Text] [Related]
19. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
20. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment.
Peters BG; Goeckner BJ; Ponzillo JJ; Velasquez WS; Wilson AL
Formulary; 1995 Jul; 30(7):388-93. PubMed ID: 10151730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]